Evidence map›Paper›PMID 32805303›Full record

ArticleBiochimie2020

Various interferon (IFN)-inducible transmembrane (IFITM) proteins for COVID-19, is there a role for the combination of mycophenolic acid and interferon?

Razieh Dowran, Seyed Fazel Nabavi, Solomon Habtemariam, Maciej Banach, Shiva Shahmohamadnejad, Cosmin Andrei Cismaru, Ioana Berindan-Neagoe, Adeleh Sahebnasagh, Seyed Mohammad Nabavi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochimie, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 4 countries.

Razieh DowranDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Seyed Fazel NabaviApplied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran; Division of Translational Medicine, Baqiyatallah Hospital, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Solomon HabtemariamPharmacognosy Research Laboratories & Herbal Analysis Services UK, University of Greenwich, Chatham-Maritime, ME4 4TB Kent, UK.
Maciej BanachDepartment of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Poland; Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland.
Shiva ShahmohamadnejadDepartment of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Cosmin Andrei CismaruResearch Center for Functional Genomics, Biomedicine and Translational Medicine, The "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania; Department of Functional Sciences, Immunology and Allergology, The "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Ioana Berindan-NeagoeResearch Center for Functional Genomics, Biomedicine and Translational Medicine, The "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania; Functional Genomics and Experimental Pathology, The Oncology Institute "Prof. Dr. Ion Chiricuta", Cluj-Napoca, Romania.
Adeleh SahebnasaghClinical Research Center, Department of Internal Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.
Seyed Mohammad NabaviApplied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran; Division of Translational Medicine, Baqiyatallah Hospital, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address: Nabavi208@gmail.com.
Baqiyatallah University of Medical Sciences · IRTehran University of Medical Sciences · IRInstitute of Oncology Prof. Dr. Ion Chiricuta · ROIuliu Hațieganu University of Medicine and Pharmacy · RONorth Khorasan University of Medical Sciences · IRPolish Mother’s Memorial Hospital Research Institute · PLUniversity of Greenwich · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various interferon (IFN)-inducible transmembrane (IFITM) proteins are known to be expressed in human tissues though only IFITM 1-3 are inducible by IFN. Numerous studies have shown that activation of IFITM3 could suppress infection by influenza and coronaviruses such as the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). In view of the potential application of IFITM proteins' induction to target SARS-CoV-2 infection that causes COVID-19, this article layout insights into the known antiviral mechanisms and therapeutic agents related to IFITM. Blocking viral entry through various mechanisms and the potential application of the FDA approved immunosuppressant agent, mycophenolic acid, as inducer of IFITM3 are among those discussed.

Indexed as

AnimalsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentHumansImmunosuppressive AgentsInterferonsMembrane ProteinsMycophenolic AcidPandemicsPneumonia, ViralRNA-Binding ProteinsSARS-CoV-2IFITM3 protein, humanImmunosuppressive AgentsInterferonsMembrane ProteinsMycophenolic AcidRNA-Binding Proteins

Identifiers

PMID32805303
PMCPMC7426705
OpenAlexW3048506467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.